Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bioprojet

Criteria

Inclusion Criteria:

• Males or females 18 years old or more;

• Diagnosis of ischemic stroke at least one month and not more than six months prior to screening;

• Persistent fatigue since the stroke with a score ≥ 60 across all domains of the Multidimensional Fatigue Inventory (MFI-20);

• Modified Rankin Score (mRS) < 3;

• Capability to participate in all study tests according to the investigator;

• Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure;

• Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake.

Exclusion Criteria:

• Any identified etiology for fatigue other than stroke according to the investigator;

• History of psychosis;

• Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments;

• Patients at risk of suicide according to the investigator;

• Major cognitive disorders, dementia according to the investigator;

• History of epilepsy or seizures disorder;

• History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening;

• Glomerular filtration rate <60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula;

• Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 ULN, or abnormal clinical laboratory results (in most cases > 3ULN);

• Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation.